CAVANAUGH JAMES H

SEC source: 0001104659-26-029633 · tm269084-1_4seq1.xml · derivative · entry 4

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 94,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock.

F4 · derivative.exercise_date: The December 2025 RSUs vested at issuance on their grant date.

F4 · derivative.expiration_date: The December 2025 RSUs vested at issuance on their grant date.

SEC source: 0001104659-26-029633 · tm269084-1_4seq1.xml · derivative · entry 3

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 74,700 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock").

F3 · derivative.exercise_date: The November 2025 RSUs vested at issuance on their grant date.

F3 · derivative.expiration_date: The November 2025 RSUs vested at issuance on their grant date.

SEC source: 0001104659-26-029633 · tm269084-1_4seq1.xml · nonDerivative · entry 2

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock.

F2 · price: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock.

SEC source: 0001104659-26-029633 · tm269084-1_4seq1.xml · nonDerivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock").

F1 · price: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock").

SEC source: 0001104659-25-125258 · tm2534450-6_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,050

Underlying: Common Stock · 94,050 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"). The RSUs were awarded pursuant to the Company's 2025 Equity Incentive Plan for no consideration.

F2 · derivative.exercise_date: The RSUs vested at issuance on December 23, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date.

F2 · derivative.expiration_date: The RSUs vested at issuance on December 23, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date.

SEC source: 0001104659-25-114093 · tm2531740-2_4seq1.xml · nonDerivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F1 · shares: On November 17, 2025, HCV VIII Liquidating Trust ("HCV Liquidating Trust") sold 261,840 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F1 · price: On November 17, 2025, HCV VIII Liquidating Trust ("HCV Liquidating Trust") sold 261,840 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F1 · balance_after: On November 17, 2025, HCV VIII Liquidating Trust ("HCV Liquidating Trust") sold 261,840 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F1 · ownership.nature: On November 17, 2025, HCV VIII Liquidating Trust ("HCV Liquidating Trust") sold 261,840 shares of the Issuer's common stock at a price of $3.14 per share as a part of a liquidating distribution in connection with the wind up and liquidation of the entity. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $3.40. The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.

F2 · ownership.nature: The reporting person is a beneficiary of the HCV Liquidating Trust and may be deemed to have had beneficial ownership of the 261,840 shares of common stock sold by the HCV Liquidating Trust. The reporting person disclaims beneficial ownership of such shares of common sold by HCV Liquidating Trust, except to the extent of the reporting person's proportionate pecuniary interest therein.

SEC source: 0001104659-25-111438 · tm2531210-5_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,700

Underlying: Common Stock · 74,700 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"). The RSUs were awarded pursuant to the Company's 2022 Equity Incentive Plan for no consideration.

F2 · derivative.exercise_date: The RSUs vested at issuance on November 11, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date.

F2 · derivative.expiration_date: The RSUs vested at issuance on November 11, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date.

SEC source: 0001104659-24-119795 · tm2428586-4_4seq1.xml · derivative · entry 3

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value per share · 213 shares

Expires 2024-11-14

F1 · kind: On November 13, 2024, James Cavanaugh exercised a warrant to purchase 213 shares of the Issuer's common stock at an exercise price of $2.82 per share.

SEC source: 0001104659-24-119795 · tm2428586-4_4seq1.xml · nonDerivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213

F1 · kind: On November 13, 2024, James Cavanaugh exercised a warrant to purchase 213 shares of the Issuer's common stock at an exercise price of $2.82 per share.

SEC source: 0001104659-24-106332 · tm2425653-2_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-10-02

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-24-009016 · tm244775-9_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-01-29

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-23-095360 · tm2324823-6_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2033-08-23

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of November 23, 2023, February 23, 2024, May 23, 2024 and August 23, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company.

SEC source: 0001104659-23-041749 · tm2311741-8_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-03-31

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023 for so long as the reporting person continues to be a director, consultant or service provider of the Company until the Option is fully vested.

SEC source: 0001104659-22-097623 · tm2225099-4_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-08-31

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of September 1, 2022, the Vesting Start Date.

SEC source: 0001104659-22-011079 · tm225302-9_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2032-01-30

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2022, the Vesting Start Date.

SEC source: 0001104659-21-021032 · tm216410-3_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,154

Underlying: Common Stock, $0.001 par value per share · 1,154 shares

Expires 2026-02-05

F1 · kind: These warrants to purchase common stock were acquired by the reporting person in connection with a transfer (the "Transfer"), for no consideration, of warrants to purchase common stock by HealthCare Ventures IX, L.P. ("HCVIX") to the limited partners of HCVIX, including the reporting person, on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P., the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX.

F2 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer.

F1 · ownership.direct: These warrants to purchase common stock were acquired by the reporting person in connection with a transfer (the "Transfer"), for no consideration, of warrants to purchase common stock by HealthCare Ventures IX, L.P. ("HCVIX") to the limited partners of HCVIX, including the reporting person, on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P., the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX.

SEC source: 0001104659-21-001647 · tm211724-3_4seq1.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,300

Underlying: Common Stock · 32,300 shares

Expires 2031-01-03

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2021, the Vesting Start Date.

SEC source: 0001104659-20-094195 · a4.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-08-09

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three month anniversary of August 10, 2020, the Vesting Start Date.

SEC source: 0001104659-20-046077 · a4.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-04-09

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of April 9, 2020, the Vesting Start Date.

SEC source: 0001104659-20-029235 · a4.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-03-01

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2020, the Vesting Start Date.

SEC source: 0001104659-19-035076 · a4.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of June 11, 2019, the Vesting Start Date.

SEC source: 0001104659-19-000514 · a4.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2028-12-31

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 4 quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 1, 2019, the Vesting Start Date.

SEC source: 0001104659-18-048858 · a4.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,137

Underlying: Common Stock · 2,137 shares

Expires 2024-11-14

F1 · kind: Pro rata distribution from HealthCare Ventures IX, L.P., of which the reporting person is a limited partner. The reporting person is also a Managing Director of HealthCare Partners VIII, LLC, which is General Partner of HealthCare Partners VIII, L.P., which is the General Partner of HealthCare Ventures VIII, L.P. ("HCV VIII"). HCV VIII continues to hold 2,618,406 shares of common stock, representing 17.8% of the outstanding shares of common stock.

SEC source: 0001104659-18-025617 · a4.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock, $0.001 par value per share · 11,250 shares

Expires 2028-04-17

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 18, 2018, the Vesting Start Date.

F1 · derivative.underlying_shares: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 18, 2018, the Vesting Start Date.

SEC source: 0001104659-17-003613 · a4.xml · derivative · entry 2

CAVANAUGH JAMES H · CIK 0001013473 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock, $0.001 par value per share · 15,000 shares

Expires 2027-01-22

F2 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 23, 2017, the Vesting Start Date.

F2 · derivative.underlying_shares: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 12 equal quarterly installments until the Option is fully vested, with the first such quarterly installment vesting on the three-month anniversary of January 23, 2017, the Vesting Start Date.

SEC source: 0001104659-17-003613 · a4.xml · derivative · entry 1

CAVANAUGH JAMES H · CIK 0001013473 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock, $0.001 par value per share · 11,000 shares

Expires 2027-01-22

F1 · derivative.exercise_date: The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and is fully vested as of the grant date.

F1 · derivative.underlying_shares: The Option was granted pursuant to Leap's Amended and Restated 2012 Equity Incentive Plan and is fully vested as of the grant date.